Christian Hölscher spends much of his time researching Endocrinology, Internal medicine, Long-term potentiation, Liraglutide and Neuroprotection. His Endocrinology research incorporates themes from Alzheimer's disease and Neurodegeneration. His Pharmacology research extends to Internal medicine, which is thematically connected.
His Long-term potentiation research is multidisciplinary, relying on both Synaptic plasticity, Hippocampus, Neuroscience and Neurotransmission. The concepts of his Liraglutide study are interwoven with issues in Incretin and Exenatide. His studies in Neuroprotection integrate themes in fields like Signal transduction, Kinase, GSK-3 and Receptor expression.
His primary areas of study are Internal medicine, Endocrinology, Neuroprotection, Neuroscience and Pharmacology. His Internal medicine study frequently draws connections to adjacent fields such as Protein kinase B. In most of his Endocrinology studies, his work intersects topics such as Alzheimer's disease.
His Neuroprotection research includes elements of Liraglutide, Agonist, Receptor, Neurodegeneration and Parkinson's disease. His Neuroscience research is multidisciplinary, incorporating perspectives in Synaptic plasticity, Long-term potentiation, Neurotransmission and Metabotropic glutamate receptor. His studies deal with areas such as Hippocampal formation and Amyloid as well as Hippocampus.
His primary areas of investigation include Neuroprotection, Agonist, Internal medicine, Pharmacology and Endocrinology. His Neuroprotection study introduces a deeper knowledge of Neuroscience. The study incorporates disciplines such as Liraglutide, Incretin, PER2 and Circadian rhythm in addition to Agonist.
Christian Hölscher works in the field of Internal medicine, focusing on Peroxisome proliferator-activated receptor in particular. He has included themes like Substantia nigra, GIP receptor, DUAL and Tumor necrosis factor alpha in his Pharmacology study. His Endocrinology study integrates concerns from other disciplines, such as Synaptic plasticity, Long-term potentiation and Cerebral infarction.
Christian Hölscher mainly focuses on Neuroprotection, Pharmacology, Agonist, Liraglutide and Receptor. He has researched Pharmacology in several fields, including Substantia nigra, Parkinson's disease and MPTP. His Agonist research also works with subjects such as
He is exploring Water maze as part of his Internal medicine and Endocrinology and Water maze studies. His study in Endocrinology is interdisciplinary in nature, drawing from both Inflammation and Microglia. His Liraglutide study incorporates themes from Reactive oxygen species and Neuroinflammation.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Aβ42‐driven cerebral amyloidosis in transgenic mice reveals early and robust pathology
Rebecca Radde;Tristan Bolmont;Stephan A Kaeser;Janaky Coomaraswamy.
EMBO Reports (2006)
An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer’s disease–associated Aβ oligomers
Theresa R. Bomfim;Leticia Forny-Germano;Luciana B. Sathler;Jordano Brito-Moreira.
Journal of Clinical Investigation (2012)
The Diabetes Drug Liraglutide Prevents Degenerative Processes in a Mouse Model of Alzheimer's Disease
Paula L. McClean;Vadivel Parthsarathy;Emilie Faivre;Christian Hölscher.
The Journal of Neuroscience (2011)
Nitric oxide, the enigmatic neuronal messenger: its role in synaptic plasticity
Trends in Neurosciences (1997)
Stimulation on the Positive Phase of Hippocampal Theta Rhythm Induces Long-Term Potentiation That Can Be Depotentiated by Stimulation on the Negative Phase in Area CA1 In Vivo
Christian Hölscher;Roger Anwyl;Michael J. Rowan.
The Journal of Neuroscience (1997)
Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis.
Kerry Hunter;Christian Hölscher.
BMC Neuroscience (2012)
Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence.
Jessica Freiherr;Manfred Hallschmid;William H. Frey;Yvonne F. Brünner.
CNS Drugs (2013)
Common pathological processes in Alzheimer disease and type 2 diabetes: a review.
Lin Li;Christian Hölscher.
Brain Research Reviews (2007)
Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer’s-like pathology
Adrian Olmos-Alonso;Sjoerd T. T. Schetters;Sarmi Sri;Katharine Askew.
Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer’s disease.
Paula L. McClean;Christian Hölscher.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: